Veracyte Inc
NASDAQ:VCYT
Veracyte Inc
Cost of Revenue
Veracyte Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Veracyte Inc
NASDAQ:VCYT
|
Cost of Revenue
-$147.6m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-24%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
-$16.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
-$6.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
-$12.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
-$1.5B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-38%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
-$1.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-25%
|
|
Veracyte Inc
Glance View
Veracyte Inc., founded in 2008, operates at the intriguing intersection of biotechnology and diagnostics, leveraging genomic insights to transform the landscape of disease diagnosis. The company's core mission is to improve the accuracy and efficiency of diagnostic testing, thus enabling better treatment decisions. Veracyte has woven innovation into its business model, creating a suite of genomic tests primarily for oncology and pulmonology. These tests are designed to resolve diagnostic ambiguity, particularly in cases where traditional tests might fall short. By harnessing advanced genomic technology, Veracyte empowers healthcare providers with definitive answers, thus facilitating timely and appropriate patient management. The company's revenue engine is driven by its extensive portfolio of products and services. At the heart of its operations is a series of diagnostic tests—such as Afirma for thyroid cancer, Percepta for lung cancer, and Envisia for idiopathic pulmonary fibrosis—each of which addresses key unmet medical needs. Veracyte generates income by selling these tests primarily to hospitals and healthcare providers, who in turn utilize the insights to bolster their clinical decision-making. Additionally, the company licenses its proprietary biobank and genomic platform to partners in research and pharma industries, unlocking further monetary streams. As payers increasingly recognize and reimburse the value of these precision diagnostic tools, Veracyte continues to strategically expand its market reach, reinforcing its role as a vital player in the biotech domain.
See Also
What is Veracyte Inc's Cost of Revenue?
Cost of Revenue
-147.6m
USD
Based on the financial report for Dec 31, 2024, Veracyte Inc's Cost of Revenue amounts to -147.6m USD.
What is Veracyte Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-24%
Over the last year, the Cost of Revenue growth was -31%. The average annual Cost of Revenue growth rates for Veracyte Inc have been -26% over the past three years , -32% over the past five years , and -24% over the past ten years .
You don't have any saved screeners yet